POS0374 MONITORING CHRONIC INFLAMMATORY MUSCULOSKELETAL DISEASES WITH A PRECISION DIGITAL COMPANION PLATFORM(TM)–RESULTS OF THE DIGIREUMA FEASIBILITY STUDY
Authors: D. Benavent, F. J. Núñez-Benjumea, L. Fernández-Luque, V. Navarro-Compán, M. Sanz, E. Calvo Aranda, L. Lojo, A. Balsa, C. Plasencia
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that is limited by the capacity of healthcare professionals. Innovative tools need to be implemented effectively in the clinical care of patients with RMDs. Objectives To test the feasibility of a Precision Digital Companion Platform ™ for real-time monitoring of disease outcomes in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Methods Digireuma was a prospective study including patients with RA and SpA, using the digital Precision Digital Companion Platform, Adhera for Rheumatology ( ISRCTN11896540 ). During a follow-up of 3 months, patients were asked to report disease specific electronic patient reported outcomes (ePROs) on a regular basis in the mobile solution. Two rheumatologists monitored these ePROs and, patients were contacted for online or face-to-face interventions when deemed necessary by clinicians (Figure 1). Assessment measures included patient global assessment (PGA) of disease activity, tender joint count (TJC), swollen joint count (SJC), Health Assessment Questionnaire (HAQ) and pain visual analogue scale (VAS), for patients with RA; VAS, PGA, TJC, SJC, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and ASAS Health Index (ASAS-HI), for patients with SpA. In addition, flares, changes in medication and recent infections were asked. Usability of the digital solution was measured by the Net-Promoter Score (NPS). Figure 1. Digital monitoring in the study powered by Adhera for Rheumatology. Screenshots in top depict the mobile interface (left) and clinical web application (right) Results Forty-six patients were recruited of whom 22 had RA and 24 SpA. Mean age was 48 ± 12 and 42 ± 9 years in the RA and SpA groups, respectively. 18/22 (82%) patients with RA and 9/24 (38%) with SpA were female. Among the total included patients, 41 (89%) completed the onboarding (18/22 (82%) RA, 23/24 (96%) SpA) and 37 (80%) submitted at least one entry. In the RA group who completed the onboarding (n=18) there were a total of 4019 total interactions (2178 questionnaire items, 648 accesses to educational units, 105 quizzes, 1088 rated messages), while patients with SpA (n=23) had a total of 3160 interactions (1637 questionnaire items, 684 accesses to educational units, 77 quizzes, 762 rated messages). ePROs measurements completion rates for RA and SpA patients that completed any data during follow-up are shown in Table 1. Patients with RA completed a median of 9.5 ePROs during follow-up, whereas patients with SpA completed a median of 3. Regarding alerts, 15 patients generated a total of 26 alerts, of which 24 were flares (10 RA, 14 SpA) and 2 were problems with the medication (1 RA, 1 SpA). 18 (69%) of the alerts were managed remotely, 5 (19%) required a face-to-face intervention and in 3 (12%) patients did not respond before the consultation. Regarding usability and patient satisfaction, 14 patients provided feedback. According to the NPS, 9/14 were considered promoters, 4/14 passives and 1/14 detractor. The overall rating of these 14 patients for the app was 4.3 out of 5 stars. Table 1. Onboarded patient engagement with regards to e-PROs Rheumatoid Arthritis (n=18) PGA TJC SJC VAS HAQ Total ePROs completed 1.5 (0.25, 3) 2 (0.25, 3) 2 (0.25, 3) 2 (0, 3) 2 (1, 3) 9.5 (4.3, 15.8) Patients with ≥ 1 entry 13 (72.2) 13 (72.2) 13 (72.2) 12 (66.7) 16 (88.9) 16 (88.9) Spondyloarthritis (n=23 ) PGA TJC SJC BASDAI ASAS-HI Total ePROs completed 1 (0,3) 1 (0,3) 1 (0,3) 1 (0,2) 1 (0,2) 3 (1, 12) Patients with ≥ 1 entry 16 (69.5) 16 (69.5) 16 (69.5) 14 (60.8) 14 (60.8) 21 (91.3) Follow-up period was 3 months. Results are expressed in median (Q1, Q3) and n (%) Conclusion This study shows that the use of a digital health solution is feasible in clinical practice. Based on these preliminary results, the next step will be to further implement the Precision Digital Companion Platform, Adhera for Rheumatology, in a multicentric setting to analyze the added value for monitoring patients. Acknowledgements This study was funded with an unrestricted grant from Abbvie. Disclosure of Interests Diego Benavent Speakers bureau: Jannsen, Roche, Grant/research support from: Novartis, Abbvie, Francisco J. Núñez-Benjumea Employee of: AdheraHealth Inc, Luis Fernández-Luque Employee of: AdheraHealth Inc, Victoria Navarro-Compán Speakers bureau: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie and Novartis, María Sanz: None declared, Enrique Calvo Aranda Speakers bureau: Abbvie, LETICIA LOJO: None declared, Alejandro Balsa Speakers bureau: Pfizer, Abbvie, Lilly, Galapagos, BMS, Sandoz, Nordic Pharma, Gebro, Roche, Sanofi, UCB, Consultant of: Pfizer, Abbvie, Lilly, Galapagos, BMS, Nordic Pharma, Sanofi, UCB, Grant/research support from: Pfizer, Abbvie, BMS, Nordic Pharma, Gebro, Roche, UCB, Chamaida Plasencia Speakers bureau: Pfizer, Abbvie, Lilly, Sandoz, Sanofi, Biogen, Roche, Novartis, Grant/research support from: Pfizer y Abbvie